---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-043061"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2022-11-25T23:59:59+00:00"
generated_at: "2026-06-21T13:10:13.872752+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics raises $7.7M via private placement of units with warrants

## Summary
- Offered 2,184,950 units at $3.53 each, each unit consisting of one share and two warrants exercisable at $3.28 per share for five-and-a-half years.
- Insiders Chairman Charles Cherington and director Nicholas Singer participated on same terms as other investors.
- Closing expected December 2, 2022; net proceeds to be used for general working capital.
- Warrants exercisable six months after closing, with beneficial ownership limitations of 4.99% (adjustable to 9.99%).
- Securities offered under Section 4(a)(2) and Regulation D; resale registration rights to be filed within 30 days of S-3 eligibility.

## SEC filing metadata
- accession: 0001140361-22-043061
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2022-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036122043061/0001140361-22-043061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036122043061/brhc10044682_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-043061
- JSON: https://secwatch.observer/filing/0001140361-22-043061.json
- Plain text: https://secwatch.observer/filing/0001140361-22-043061.txt

## Key facts
- Material Agreements
  Ernexa Therapeutics Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $ 7.7 million (effective 2022-11-23).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: approximately $ 7.7 million
  - Effective: 2022-11-23
  source text: On November 23, 2022, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain investors (the “ Purchasers ”) providing for the private placement (the “ Private Placement ”) to the Purchasers of an aggregate of 2,184,950 units (collectively, the “ Units ”), each Unit consisting of (i) one share of the Company’s common stock, par value $0.005 per share (“ Common Stock ”) and (ii) two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share (the “ Warrants ”), for an aggregate purchase price of approximately $ 7.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122043061/0001140361-22-043061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.